Highlights
Topical ripasudil (K-321) given four times daily after Descemet stripping only (DSO) significantly improved central endothelial cell density at 12 weeks compared with placebo in patients with Fuchs endothelial corneal dystrophy (FECD).
Clinical recovery was also faster: corneal edema cleared in 81.0% of patients in the QID group versus 9.1% in the placebo group, and rescue therapy was needed less often.
